Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT01865747
Registration number
NCT01865747
Ethics application status
Date submitted
21/05/2013
Date registered
31/05/2013
Date last updated
27/04/2021
Titles & IDs
Public title
A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma
Query!
Scientific title
A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy
Query!
Secondary ID [1]
0
0
XL184-308
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
METEOR
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Renal Cell Carcinoma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Non melanoma skin cancer
Query!
Cancer
0
0
0
0
Query!
Kidney
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Experimental: Cabozantinib (XL184) - Cabozantinib (XL184) 60 mg tablet once daily.
Active comparator: Everolimus (Afinitor) - Everolimus (Afinitor) 10 mg tablet once daily.
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Progression-free Survival (PFS)
Query!
Assessment method [1]
0
0
The primary analysis of PFS is the time from randomization to date of first documented tumor progression as determined by investigator (per RECIST 1.1 criteria) or death due to any cause, whichever occurred first. A Kaplan-Meier analysis was performed to estimate the median duration.
Query!
Timepoint [1]
0
0
PFS is measured from the date of randomization until the date of first documented disease progression or date of death from any cause as determined by the Independent Radiology Committee (IRC) per RECIST 1.1, assessed for up to 17 months.
Query!
Secondary outcome [1]
0
0
Overall Survival (OS)
Query!
Assessment method [1]
0
0
Overall Survival (OS) is defined as the time from randomization to the date of death. Participants that had not died were censored at last known date alive. Median OS was calculated using Kaplan-Meier estimates. Interim analyses for OS occurred after 320 deaths (78% of the total OS events needed for final analysis).
Query!
Timepoint [1]
0
0
OS was measured from the time of randomization until 320 deaths, approximately 28 months
Query!
Secondary outcome [2]
0
0
Objective Response Rate (ORR)
Query!
Assessment method [2]
0
0
Objective Response Rate (ORR) is the number of participants with a best response of complete response (CR) or partial response (PR) divided by number of randomized participants. ORR was assessed by the Independent Radiology Committee (IRC) per RECIST 1.1 which was confirmed by a subsequent visit \>= 28 days later, and was analyzed in the Intent to Treat (ITT) population at the time of the primary analysis of Progression Free Survival (PFS). The data cutoff date was 22 May 2015.
Query!
Timepoint [2]
0
0
ORR was assessed at 8 weeks post-randomization, every 8 weeks for 12 months, and every 12 weeks until date of disease progression or death, up to May 2015 (approximately 21 months)
Query!
Eligibility
Key inclusion criteria
Select
1. Documented histological or cytological diagnosis of renal cell cancer with a clear-cell component.
2. Measurable disease as determined by the investigator.
3. Must have received at least one VEGFR-targeting TKI (eg, sorafenib, sunitinib, axitinib, pazopanib or tivozanib).
4. Recovery from toxicities related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy.
5. Adequate organ and marrow function.
6. Sexually active fertile subjects(male and female)must agree to use medically accepted methods of contraception during the course of the study and for 4 months after the last dose of study treatment.
7. Female subjects of childbearing potential must not be pregnant at screening.
Select
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Prior treatment with everolimus, or any other specific or selective TORC1/PI3K/AKT inhibitor (eg, temsirolimus), or cabozantinib.
2. Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before randomization.
3. Receipt of any type of anticancer antibody (including investigational antibody) within 4 weeks before randomization.
4. Radiation therapy for bone metastasis within 2 weeks, any other external radiation therapy within 4 weeks before randomization. Systemic treatment with radionuclides within 6 weeks before randomization. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible.
5. Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery and stable for at least 3 months before randomization.
6. Concomitant anticoagulation at therapeutic doses with oral anticoagulants or platelet inhibitors.
7. Chronic treatment with corticosteroids or other immunosuppressive agents.
8. Serious illness other than cancer.
9. Major surgery within 3 months before randomization. Complete wound healing from major surgery must have occurred 1 month before randomization and from minor surgery at least 10 days before randomization.
10. Pregnant or lactating females.
11. Diagnosis of another malignancy within 2 years before randomization, except for superficial skin cancers, or localized, low grade tumors.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/06/2013
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
15/01/2021
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
658
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,TAS,VIC
Query!
Recruitment hospital [1]
0
0
- Concord
Query!
Recruitment hospital [2]
0
0
- Darlinghurst
Query!
Recruitment hospital [3]
0
0
- Kogarah
Query!
Recruitment hospital [4]
0
0
- Port Macquarie
Query!
Recruitment hospital [5]
0
0
- Randwick
Query!
Recruitment hospital [6]
0
0
- Wahroonga
Query!
Recruitment hospital [7]
0
0
- Westmead
Query!
Recruitment hospital [8]
0
0
- Milton
Query!
Recruitment hospital [9]
0
0
- Wooloongabba
Query!
Recruitment hospital [10]
0
0
- Adelaide
Query!
Recruitment hospital [11]
0
0
- Hobart
Query!
Recruitment hospital [12]
0
0
- Bentleight East
Query!
Recruitment hospital [13]
0
0
- Box Hill
Query!
Recruitment hospital [14]
0
0
- Wodonga
Query!
Recruitment postcode(s) [1]
0
0
2139 - Concord
Query!
Recruitment postcode(s) [2]
0
0
2010 - Darlinghurst
Query!
Recruitment postcode(s) [3]
0
0
2217 - Kogarah
Query!
Recruitment postcode(s) [4]
0
0
- Port Macquarie
Query!
Recruitment postcode(s) [5]
0
0
2031 - Randwick
Query!
Recruitment postcode(s) [6]
0
0
2076 - Wahroonga
Query!
Recruitment postcode(s) [7]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [8]
0
0
4064 - Milton
Query!
Recruitment postcode(s) [9]
0
0
4102 - Wooloongabba
Query!
Recruitment postcode(s) [10]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [11]
0
0
7000 - Hobart
Query!
Recruitment postcode(s) [12]
0
0
3165 - Bentleight East
Query!
Recruitment postcode(s) [13]
0
0
3128 - Box Hill
Query!
Recruitment postcode(s) [14]
0
0
3690 - Wodonga
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Alaska
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Arizona
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
California
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Colorado
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Connecticut
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
District of Columbia
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Florida
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Illinois
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Iowa
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Kansas
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Maryland
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Massachusetts
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Michigan
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Minnesota
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Missouri
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Nevada
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
New York
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
North Carolina
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Ohio
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Oregon
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Pennsylvania
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
South Carolina
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Tennessee
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Texas
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Utah
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Washington
Query!
Country [28]
0
0
Argentina
Query!
State/province [28]
0
0
Buenos Aires
Query!
Country [29]
0
0
Argentina
Query!
State/province [29]
0
0
Mar Del Plata
Query!
Country [30]
0
0
Austria
Query!
State/province [30]
0
0
Oberösterreich
Query!
Country [31]
0
0
Austria
Query!
State/province [31]
0
0
Wien
Query!
Country [32]
0
0
Belgium
Query!
State/province [32]
0
0
Antwerpen
Query!
Country [33]
0
0
Belgium
Query!
State/province [33]
0
0
Brussels
Query!
Country [34]
0
0
Belgium
Query!
State/province [34]
0
0
Vlaams Brabant
Query!
Country [35]
0
0
Belgium
Query!
State/province [35]
0
0
West-Vlaanderen
Query!
Country [36]
0
0
Belgium
Query!
State/province [36]
0
0
Liege
Query!
Country [37]
0
0
Canada
Query!
State/province [37]
0
0
Alberta
Query!
Country [38]
0
0
Canada
Query!
State/province [38]
0
0
British Columbia
Query!
Country [39]
0
0
Canada
Query!
State/province [39]
0
0
Manitoba
Query!
Country [40]
0
0
Canada
Query!
State/province [40]
0
0
Nova Scotia
Query!
Country [41]
0
0
Canada
Query!
State/province [41]
0
0
Ontario
Query!
Country [42]
0
0
Canada
Query!
State/province [42]
0
0
Quebec
Query!
Country [43]
0
0
Canada
Query!
State/province [43]
0
0
Saskatchewan
Query!
Country [44]
0
0
Chile
Query!
State/province [44]
0
0
Santiago
Query!
Country [45]
0
0
Czechia
Query!
State/province [45]
0
0
Olomoucký Kraj
Query!
Country [46]
0
0
Czechia
Query!
State/province [46]
0
0
Brno
Query!
Country [47]
0
0
Czechia
Query!
State/province [47]
0
0
Prague
Query!
Country [48]
0
0
Denmark
Query!
State/province [48]
0
0
Hovedstaden
Query!
Country [49]
0
0
Denmark
Query!
State/province [49]
0
0
Midtjylland
Query!
Country [50]
0
0
Denmark
Query!
State/province [50]
0
0
Syddanmark
Query!
Country [51]
0
0
Finland
Query!
State/province [51]
0
0
Länsi-Suomen Lääni
Query!
Country [52]
0
0
Finland
Query!
State/province [52]
0
0
Helsinki
Query!
Country [53]
0
0
France
Query!
State/province [53]
0
0
Calvados
Query!
Country [54]
0
0
France
Query!
State/province [54]
0
0
Doubs
Query!
Country [55]
0
0
France
Query!
State/province [55]
0
0
Gironde
Query!
Country [56]
0
0
France
Query!
State/province [56]
0
0
Haute-Garonne
Query!
Country [57]
0
0
France
Query!
State/province [57]
0
0
Ille-et-Vilaine
Query!
Country [58]
0
0
France
Query!
State/province [58]
0
0
Loire-Atlantique
Query!
Country [59]
0
0
France
Query!
State/province [59]
0
0
Rhône
Query!
Country [60]
0
0
France
Query!
State/province [60]
0
0
Sarthe
Query!
Country [61]
0
0
France
Query!
State/province [61]
0
0
Val-de-Marne
Query!
Country [62]
0
0
France
Query!
State/province [62]
0
0
Marseille
Query!
Country [63]
0
0
France
Query!
State/province [63]
0
0
Paris
Query!
Country [64]
0
0
Germany
Query!
State/province [64]
0
0
Baden Wuttemberg
Query!
Country [65]
0
0
Germany
Query!
State/province [65]
0
0
Baden-Württemberg
Query!
Country [66]
0
0
Germany
Query!
State/province [66]
0
0
Bayern
Query!
Country [67]
0
0
Germany
Query!
State/province [67]
0
0
Nordrhein-Westfalen
Query!
Country [68]
0
0
Germany
Query!
State/province [68]
0
0
Rheinland-Pfalz
Query!
Country [69]
0
0
Germany
Query!
State/province [69]
0
0
Thuringen
Query!
Country [70]
0
0
Germany
Query!
State/province [70]
0
0
Thüringen
Query!
Country [71]
0
0
Germany
Query!
State/province [71]
0
0
Berlin
Query!
Country [72]
0
0
Germany
Query!
State/province [72]
0
0
Dresden
Query!
Country [73]
0
0
Germany
Query!
State/province [73]
0
0
Frankfurt am Main
Query!
Country [74]
0
0
Germany
Query!
State/province [74]
0
0
Guetersloh
Query!
Country [75]
0
0
Germany
Query!
State/province [75]
0
0
Hamburg
Query!
Country [76]
0
0
Germany
Query!
State/province [76]
0
0
Hannover
Query!
Country [77]
0
0
Germany
Query!
State/province [77]
0
0
Heidelberg
Query!
Country [78]
0
0
Germany
Query!
State/province [78]
0
0
Munchen
Query!
Country [79]
0
0
Germany
Query!
State/province [79]
0
0
Munich
Query!
Country [80]
0
0
Hungary
Query!
State/province [80]
0
0
Budapest
Query!
Country [81]
0
0
Hungary
Query!
State/province [81]
0
0
Szolnok
Query!
Country [82]
0
0
Ireland
Query!
State/province [82]
0
0
Dublin
Query!
Country [83]
0
0
Italy
Query!
State/province [83]
0
0
Emilia-Romagna
Query!
Country [84]
0
0
Italy
Query!
State/province [84]
0
0
Lazio
Query!
Country [85]
0
0
Italy
Query!
State/province [85]
0
0
Liguria
Query!
Country [86]
0
0
Italy
Query!
State/province [86]
0
0
Lombardia
Query!
Country [87]
0
0
Italy
Query!
State/province [87]
0
0
Puglia
Query!
Country [88]
0
0
Italy
Query!
State/province [88]
0
0
Toscana
Query!
Country [89]
0
0
Italy
Query!
State/province [89]
0
0
Umbria
Query!
Country [90]
0
0
Korea, Republic of
Query!
State/province [90]
0
0
Seoul
Query!
Country [91]
0
0
Netherlands
Query!
State/province [91]
0
0
Limburg
Query!
Country [92]
0
0
Netherlands
Query!
State/province [92]
0
0
Noord-Holland
Query!
Country [93]
0
0
Netherlands
Query!
State/province [93]
0
0
Zuid-Holland
Query!
Country [94]
0
0
Poland
Query!
State/province [94]
0
0
Podlaskie
Query!
Country [95]
0
0
Poland
Query!
State/province [95]
0
0
Pomorskie
Query!
Country [96]
0
0
Poland
Query!
State/province [96]
0
0
Wielkopolskie
Query!
Country [97]
0
0
Poland
Query!
State/province [97]
0
0
Warsaw
Query!
Country [98]
0
0
Portugal
Query!
State/province [98]
0
0
Lisbon
Query!
Country [99]
0
0
Portugal
Query!
State/province [99]
0
0
Porto
Query!
Country [100]
0
0
Russian Federation
Query!
State/province [100]
0
0
Moscow
Query!
Country [101]
0
0
Russian Federation
Query!
State/province [101]
0
0
Omsk
Query!
Country [102]
0
0
Russian Federation
Query!
State/province [102]
0
0
St. Petersburg
Query!
Country [103]
0
0
Russian Federation
Query!
State/province [103]
0
0
Yaroslavl
Query!
Country [104]
0
0
Slovakia
Query!
State/province [104]
0
0
Presov
Query!
Country [105]
0
0
Slovakia
Query!
State/province [105]
0
0
Zilina
Query!
Country [106]
0
0
Spain
Query!
State/province [106]
0
0
Asturias
Query!
Country [107]
0
0
Spain
Query!
State/province [107]
0
0
Cataluna
Query!
Country [108]
0
0
Spain
Query!
State/province [108]
0
0
Cataluña
Query!
Country [109]
0
0
Spain
Query!
State/province [109]
0
0
Navarra
Query!
Country [110]
0
0
Spain
Query!
State/province [110]
0
0
Barcelona
Query!
Country [111]
0
0
Spain
Query!
State/province [111]
0
0
Madrid
Query!
Country [112]
0
0
Spain
Query!
State/province [112]
0
0
Málaga
Query!
Country [113]
0
0
Spain
Query!
State/province [113]
0
0
Santiago de Compostela
Query!
Country [114]
0
0
Spain
Query!
State/province [114]
0
0
Seville
Query!
Country [115]
0
0
Spain
Query!
State/province [115]
0
0
Valencia
Query!
Country [116]
0
0
Sweden
Query!
State/province [116]
0
0
Skane Lan
Query!
Country [117]
0
0
Sweden
Query!
State/province [117]
0
0
Sodermanlands Lan
Query!
Country [118]
0
0
Sweden
Query!
State/province [118]
0
0
Umea
Query!
Country [119]
0
0
Taiwan
Query!
State/province [119]
0
0
Taichung
Query!
Country [120]
0
0
Taiwan
Query!
State/province [120]
0
0
Taipei
Query!
Country [121]
0
0
Turkey
Query!
State/province [121]
0
0
Ankara
Query!
Country [122]
0
0
Turkey
Query!
State/province [122]
0
0
Gaziantep
Query!
Country [123]
0
0
Turkey
Query!
State/province [123]
0
0
Istanbul
Query!
Country [124]
0
0
Turkey
Query!
State/province [124]
0
0
Izmir
Query!
Country [125]
0
0
United Kingdom
Query!
State/province [125]
0
0
England
Query!
Country [126]
0
0
United Kingdom
Query!
State/province [126]
0
0
Scotland
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Exelixis
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to evaluate the effect of Cabozantinib (XL184) compared with Everolimus (Afinitor) on progression-free survival (PFS) and overall survival (OS) in subjects with advanced renal cell cancer that has progressed after prior VEGFR tyrosine kinase inhibitor therapy.
Query!
Trial website
https://clinicaltrials.gov/study/NCT01865747
Query!
Trial related presentations / publications
Denize T, Farah S, Cimadamore A, Flaifel A, Walton E, Sticco-Ivins MA, Labaki C, Braun DA, Sun M, Wang E, Xie W, Choueiri TK, Signoretti S. Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial. Clin Cancer Res. 2022 Feb 15;28(4):748-755. doi: 10.1158/1078-0432.CCR-21-3088. Powles T, Choueiri TK, Motzer RJ, Jonasch E, Pal S, Tannir NM, Signoretti S, Kaldate R, Scheffold C, Wang E, Aftab DT, Escudier B, George DJ. Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. BMC Cancer. 2021 Aug 7;21(1):904. doi: 10.1186/s12885-021-08630-w. Erratum In: BMC Cancer. 2021 Sep 15;21(1):1023. doi: 10.1186/s12885-021-08693-9. Donskov F, Motzer RJ, Voog E, Hovey E, Grullich C, Nott LM, Cuff K, Gil T, Jensen NV, Chevreau C, Negrier S, Depenbusch R, Bergmann L, Cornelio I, Champsaur A, Escudier B, Pal S, Powles T, Choueiri TK. Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma. Eur J Cancer. 2020 Feb;126:1-10. doi: 10.1016/j.ejca.2019.10.032. Epub 2019 Dec 27. Flaifel A, Xie W, Braun DA, Ficial M, Bakouny Z, Nassar AH, Jennings RB, Escudier B, George DJ, Motzer RJ, Morris MJ, Powles T, Wang E, Huang Y, Freeman GJ, Choueiri TK, Signoretti S. PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. Clin Cancer Res. 2019 Oct 15;25(20):6080-6088. doi: 10.1158/1078-0432.CCR-19-1135. Epub 2019 Aug 1. Cella D, Escudier B, Tannir NM, Powles T, Donskov F, Peltola K, Schmidinger M, Heng DYC, Mainwaring PN, Hammers HJ, Lee JL, Roth BJ, Marteau F, Williams P, Baer J, Mangeshkar M, Scheffold C, Hutson TE, Pal S, Motzer RJ, Choueiri TK. Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial. J Clin Oncol. 2018 Mar 10;36(8):757-764. doi: 10.1200/JCO.2017.75.2170. Epub 2018 Jan 29. Escudier B, Powles T, Motzer RJ, Olencki T, Aren Frontera O, Oudard S, Rolland F, Tomczak P, Castellano D, Appleman LJ, Drabkin H, Vaena D, Milwee S, Youkstetter J, Lougheed JC, Bracarda S, Choueiri TK. Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial. J Clin Oncol. 2018 Mar 10;36(8):765-772. doi: 10.1200/JCO.2017.74.7352. Epub 2018 Jan 8. Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, Hammers HJ, Donskov F, Roth BJ, Peltola K, Lee JL, Heng DYC, Schmidinger M, Agarwal N, Sternberg CN, McDermott DF, Aftab DT, Hessel C, Scheffold C, Schwab G, Hutson TE, Pal S, Motzer RJ; METEOR investigators. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016 Jul;17(7):917-927. doi: 10.1016/S1470-2045(16)30107-3. Epub 2016 Jun 5. Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, Roth BJ, Bjarnason GA, Geczi L, Keam B, Maroto P, Heng DY, Schmidinger M, Kantoff PW, Borgman-Hagey A, Hessel C, Scheffold C, Schwab GM, Tannir NM, Motzer RJ; METEOR Investigators. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015 Nov 5;373(19):1814-23. doi: 10.1056/NEJMoa1510016. Epub 2015 Sep 25.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT01865747
Download to PDF